216 related articles for article (PubMed ID: 22796905)
41. Galantamine treatment of vascular dementia: a randomized trial.
Auchus AP; Brashear HR; Salloway S; Korczyn AD; De Deyn PP; Gassmann-Mayer C;
Neurology; 2007 Jul; 69(5):448-58. PubMed ID: 17664404
[TBL] [Abstract][Full Text] [Related]
42. Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression.
Farlow MR; Hake A; Messina J; Hartman R; Veach J; Anand R
Arch Neurol; 2001 Mar; 58(3):417-22. PubMed ID: 11255445
[TBL] [Abstract][Full Text] [Related]
43. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease.
Wilkinson DG; Passmore AP; Bullock R; Hopker SW; Smith R; Potocnik FC; Maud CM; Engelbrecht I; Hock C; Ieni JR; Bahra RS
Int J Clin Pract; 2002; 56(6):441-6. PubMed ID: 12166542
[TBL] [Abstract][Full Text] [Related]
44. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease.
Burn D; Emre M; McKeith I; De Deyn PP; Aarsland D; Hsu C; Lane R
Mov Disord; 2006 Nov; 21(11):1899-907. PubMed ID: 16960863
[TBL] [Abstract][Full Text] [Related]
45. Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch.
Molinuevo JL; Frölich L; Grossberg GT; Galvin JE; Cummings JL; Krahnke T; Strohmaier C
Alzheimers Res Ther; 2015; 7(1):9. PubMed ID: 25755685
[TBL] [Abstract][Full Text] [Related]
46. Rivastigmine patch and massage for Alzheimer's disease patients.
Satoh S; Kajiwara M; Kiyokawa E; Toukairin Y; Fujii M; Sasaki H
Geriatr Gerontol Int; 2013 Apr; 13(2):515-6. PubMed ID: 23551354
[No Abstract] [Full Text] [Related]
47. Efficacy and tolerability of rivastigmine patch therapy in patients with mild-to-moderate Alzheimer's dementia associated with minimal and moderate ischemic white matter hyperintensities: A multicenter prospective open-label clinical trial.
Park KW; Kim EJ; Han HJ; Shim YS; Kwon JC; Ku BD; Park KH; Yi HA; Kim KK; Yang DW; Lee HW; Kang H; Kwon OD; Kim S; Lee JH; Chung EJ; Park SW; Park MY; Yoon B; Kim BC; Seo SW; Choi SH
PLoS One; 2017; 12(8):e0182123. PubMed ID: 28786987
[TBL] [Abstract][Full Text] [Related]
48. Rivastigmine transdermal patch 13.3 mg/24 h: a review of its use in the management of mild to moderate Alzheimer's dementia.
Frampton JE
Drugs Aging; 2014 Aug; 31(8):639-49. PubMed ID: 24989628
[TBL] [Abstract][Full Text] [Related]
49. Predictors of long-term treatment effect of rivastigmine in Alzheimer's disease: a role for beta-amyloid plasma levels?
Sobów T; Kłoszewska I; Flirski M; Liberski P
Neurol Neurochir Pol; 2009; 43(6):507-16. PubMed ID: 20054753
[TBL] [Abstract][Full Text] [Related]
50. Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's disease.
Cummings JL; Farlow MR; Meng X; Tekin S; Olin JT
Clin Drug Investig; 2010; 30(1):41-9. PubMed ID: 19995097
[TBL] [Abstract][Full Text] [Related]
51. Real-life effectiveness and tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease: the EMBRACE study.
Gauthier S; Robillard A; Cohen S; Black S; Sampalis J; Colizza D; de Takacsy F; Schecter R;
Curr Med Res Opin; 2013 Aug; 29(8):989-1000. PubMed ID: 23647369
[TBL] [Abstract][Full Text] [Related]
52. Patient and caregiver outcomes after 6 +/- 1.5-months of rivastigmine therapy for mild-to-moderate Alzheimer's disease: the Belgian FExT study.
Mets T; Vandewoude M; Jacquy J; Deblander A; MacDonald K; Sloesen A; Abraham I;
Curr Med Res Opin; 2007 Oct; 23(10):2485-501. PubMed ID: 17784995
[TBL] [Abstract][Full Text] [Related]
53. Safety and tolerability of the rivastigmine patch: results of a 28-week open-label extension.
Grossberg G; Sadowsky C; Fröstl H; Frölich L; Nagel J; Tekin S; Zechner S; Ros J; Orgogozo JM
Alzheimer Dis Assoc Disord; 2009; 23(2):158-64. PubMed ID: 19484917
[TBL] [Abstract][Full Text] [Related]
54. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.
Rösler M; Anand R; Cicin-Sain A; Gauthier S; Agid Y; Dal-Bianco P; Stähelin HB; Hartman R; Gharabawi M
BMJ; 1999 Mar; 318(7184):633-8. PubMed ID: 10066203
[TBL] [Abstract][Full Text] [Related]
55. Two-year treatment of Alzheimer's disease with eptastigmine. The Eptastigmine Study Group.
Imbimbo BP; Verdelli G; Martelli P; Marchesini D
Dement Geriatr Cogn Disord; 1999; 10(2):139-47. PubMed ID: 10026388
[TBL] [Abstract][Full Text] [Related]
56. Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease.
Feldman HH; Lane R;
J Neurol Neurosurg Psychiatry; 2007 Oct; 78(10):1056-63. PubMed ID: 17353259
[TBL] [Abstract][Full Text] [Related]
57. Reviews: Effects of transdermal rivastigmine on ADAS-cog items in mild-to-moderate Alzheimer's disease.
Grossberg GT; Schmitt FA; Meng X; Tekin S; Olin J
Am J Alzheimers Dis Other Demen; 2010 Dec; 25(8):627-33. PubMed ID: 21131668
[TBL] [Abstract][Full Text] [Related]
58. Long-term safety of rivastigmine in parkinson disease dementia: an open-label, randomized study.
Emre M; Poewe W; De Deyn PP; Barone P; Kulisevsky J; Pourcher E; van Laar T; Storch A; Micheli F; Burn D; Durif F; Pahwa R; Callegari F; Tenenbaum N; Strohmaier C
Clin Neuropharmacol; 2014; 37(1):9-16. PubMed ID: 24434526
[TBL] [Abstract][Full Text] [Related]
59. Impact of rivastigmine patch and capsules on activities of daily living in Alzheimer's disease.
Grossberg G; Meng X; Olin JT
Am J Alzheimers Dis Other Demen; 2011 Feb; 26(1):65-71. PubMed ID: 21282280
[TBL] [Abstract][Full Text] [Related]
60. A pilot randomized controlled trial evaluating an integrated treatment of rivastigmine transdermal patch and cognitive stimulation in patients with Alzheimer's disease.
D'Onofrio G; Sancarlo D; Addante F; Ciccone F; Cascavilla L; Paris F; Elia AC; Nuzzaci C; Picoco M; Greco A; Panza F; Pilotto A
Int J Geriatr Psychiatry; 2015 Sep; 30(9):965-75. PubMed ID: 25504466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
